Schizophrenia Treatment Market Size Report 2034 | Novartis Pharmaceuticals, Zhejiang Jingxin Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., Neurocrine Biosciences, Spinogenix, Cerevel Therapeutics, LLC, LB Pharmaceuticals Inc., Merck S

DelveInsight's "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of Schizophrenia, including historical and forecasted epidemiology, as well as Schizophrenia market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Discover which therapies are expected to grab the Schizophrenia Market Share @ Schizophrenia Market Outlook- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Schizophrenia Market Report
• In March 2025:- Boehringer Ingelheim conducted a study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term.
• In March 2025:- Teva Branded Pharmaceutical Products R&D, Inc. announced a study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia.
• In the 7MM, the total Schizophrenia prevalence cases were estimated to be approximately 6,029,994 in 2022, of which the US accounted for around 45.05%, while EU4 and the UK accounted for nearly 37.36%, and Japan accounted for approximately 17.59% of the total prevalent cases.
• Among the 7MM, the US accounted for nearly 37.20% of the total Schizophrenia diagnosed prevalent cases with nearly 1,412,470 cases in 2022. These cases are expected to increase during the study period (2020-2034).
• As per DelveInsight analysis, EU4 and the UK accounted for around 1,588,816 Schizophrenia diagnosed prevalent cases in 2022. These cases are expected to change during the study period (2020-2034)
• Among the EU4 and the UK, Germany accounted for the highest Schizophrenia prevalence cases representing nearly 28.50% of the cases, followed by the UK, and France, while Spain had the least cases in 2022
• According to estimates based on DelveInsight's epidemiology model, Schizophrenia exhibits a higher male preponderance than females in the US. Of the total diagnosed prevalent cases in the US, nearly 53.63% were males and 46.37% were females, in 2022.
• In the US, when the Schizophrenia diagnosed prevalent cases were segmented based on severity, the mild group accounted for nearly 567,336 cases, in 2022. As per the analysis, these cases are expected to increase, and the moderate group contributed around 37.03% of the diagnosed prevalent cases, while the severe group contributed a minimum of 22.81% respectively in 2022.
• In 2022, among the 7MM, Japan had the second highest cases of Schizophrenia, contributing approximately 17.59% to the total prevalent cases of Schizophrenia.
• The leading Schizophrenia Companies such as Novartis Pharmaceuticals, Zhejiang Jingxin Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., Neurocrine Biosciences, Spinogenix, Cerevel Therapeutics, LLC, LB Pharmaceuticals Inc., Merck Sharp & Dohme LLC, and others.
• Promising Schizophrenia Pipeline Therapies such as AQW051, JX11502MA, HS-10380, NBI-1117568, SPG302, CVL-231, LB-102, MK0557, and Luvadaxistat, and others.

Stay ahead in the Schizophrenia Therapeutics Market with DelveInsight's Strategic Report @ Schizophrenia Market Outlook- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Schizophrenia Epidemiology Segmentation in the 7MM
• Total Schizophrenia Prevalent Cases
• Total Schizophrenia Diagnosed Cases
• Schizophrenia Gender-specific Cases
• Schizophrenia Severity-specific Cases
• Schizophrenia Age-specific Treated Cases
• Total Schizophrenia Treated Cases

Download the report to understand which factors are driving Schizophrenia Epidemiology trends @ Schizophrenia Prevalence- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Schizophrenia Marketed Drugs
• ABILIFY MAINTENA (aripiprazole): Otsuka Pharmaceutical/Lundbeck
ABILIFY MAINTENA (aripiprazole) for extended-release injectable suspension, an IM depot formulation of aripiprazole, is a sterile lyophilized powder that, when reconstituted with sterile water for injection, forms an injectable suspension that can be administered monthly. ABILIFY MAINTENA is an atypical antipsychotic drugs market. The mechanism of action of aripiprazole in the treatment of schizophrenia and bipolar I disorder is unknown. The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors.

• UZEDY (risperidone): Teva Pharmaceuticals/MedinCell
UZEDY (risperidone) extended-release injectable suspension is indicated for the treatment of schizophrenia in adults. UZEDY administers risperidone through copolymer technology under license from MedinCell that allows for absorption and sustained release in the first subcutaneous injection. UZEDY is the only long-acting, subcutaneous formulation of risperidone available in both one- and two-month dosing intervals.

Schizophrenia Emerging Drugs
• Ulotaront (SEP-363856): Sumitomo Pharma/Otsuka Pharmaceuticals
Ulotaront (SEP-363856) is a trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, jointly developed by Sunovion Pharma and PsychoGenics, which is a small-molecule oral agent that does not bind to dopamine D2 or serotonin 5-HT2A receptors. Sunovion discovered Ulotaront in collaboration with PsychoGenics using it is in vivo phenotypic SmartCube platform and associated artificial intelligence algorithms.

• Brilaroxazine (RP-5063): Reviva Pharmaceuticals
Brilaroxazine (RP5063) is a new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and other psychiatric disorders. RP5063 is a multimodal modulator of the serotonin 5-HT1A, 5-HT2A, 5-HT2B, and 5-HT7 receptors and D2, D3, and D4 dopamine receptors in clinical development for multiple neuropsychiatric indications, including schizophrenia.

To learn more about Schizophrenia treatment guidelines, visit @ Schizophrenia Treatment Market Landscape- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Schizophrenia Drugs Market Insights
Schizophrenia treatment typically involves a combination of medication and psychosocial interventions aimed at managing the condition effectively. Pharmacotherapy plays a pivotal role in addressing schizophrenia symptoms, with a wide array of mono and combination pharmacological options available. Antipsychotic medications, categorized into first-generation (FGAs) and second-generation (SGAs), are commonly prescribed as first-line treatments. Some treatment approaches may involve a combination of antipsychotics and antiepileptic medications, tailored to specific patient groups. Both oral antipsychotics (OAP) and long-acting injectable therapies (LAI) are accessible options within each generation of antipsychotics drugs market. In clinical practice, a blend of both FGAs and SGAs is often utilized to effectively manage schizophrenia symptoms.

Schizophrenia Market Outlook
Schizophrenia is a severe and chronic mental disorder characterized by distorted thinking, perception, emotions, language, sense of self, and behavior. Its impact extends beyond patients to family members, caregivers, and society due to its lifelong nature and the likelihood of relapses. The disorder progresses through stages, including prodromal, active, and residual, each marked by specific symptoms such as hallucinations, suspiciousness, delusions, depression, withdrawal, anxiety, and difficulty concentrating. The treatment options for schizophrenia include antipsychotics medicine market, psychological counseling and social support, cognitive behavioral therapy, and electroconvulsive therapy (ECT).

Learn more about the FDA-approved drugs for Schizophrenia @ Drugs for Schizophrenia Treatment- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Schizophrenia Market Report:
• Study Period: 2020-2034
• Coverage: 7MM
• Schizophrenia Companies: Novartis Pharmaceuticals, Zhejiang Jingxin Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., Neurocrine Biosciences, Spinogenix, Cerevel Therapeutics, LLC, LB Pharmaceuticals Inc., Merck Sharp & Dohme LLC, and others.
• Schizophrenia Therapies: AQW051, JX11502MA, HS-10380, NBI-1117568, SPG302, CVL-231, LB-102, MK0557, and Luvadaxistat, among others.
• Schizophrenia Therapeutic Assessment: Schizophrenia currently marketed, and Schizophrenia emerging therapies
• Schizophrenia Market Dynamics: Schizophrenia market drivers and Schizophrenia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Schizophrenia Unmet Needs, KOL's views, Analyst's views, Schizophrenia Market Access and Reimbursement

Discover more about Schizophrenia Drugs in development @ Schizophrenia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents:
1. Schizophrenia Market Report Introduction
2. Executive Summary for Schizophrenia
3. SWOT analysis of Schizophrenia
4. Schizophrenia Patient Share (%) Overview at a Glance
5. Schizophrenia Market Overview at a Glance
6. Schizophrenia Disease Background and Overview
7. Schizophrenia Epidemiology and Patient Population
8. Country-Specific Patient Population of Schizophrenia
9. Schizophrenia Current Treatment and Medical Practices
10. Schizophrenia Unmet Needs
11. Schizophrenia Emerging Therapies
12. Schizophrenia Market Outlook
13. Country-Wise Schizophrenia Market Analysis (2020-2034)
14. Schizophrenia Market Access and Reimbursement of Therapies
15. Schizophrenia Market Drivers
16. Schizophrenia Market Barriers
17. Schizophrenia Appendix
18. Schizophrenia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

List of Top Selling Market Research Reports in 2025

Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/underactive-bladder-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
Surgical sealant market - https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Ventral hernia market- https://www.delveinsight.com/report-store/hernia-repair-devices-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Trichotillomania market- https://www.delveinsight.com/report-store/trichotillomania-ttm-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/

This release was published on openPR.